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Abstract
Background: Procalcitonin (PCT) has emerged as a valuable marker of sepsis. The potential role of PCT in diagnosis
and therapy monitoring of intravascular catheter-related bloodstream infections (CRBSI) in intensive care unit (ICU)
is still unclear and was evaluated.
Methods: Forty-six patients were included in the study, provided they were free of infection upon admission and
presented the first episode of suspected CRBSI during their ICU stay. Patients who had developed any other
infection were excluded. PCT was measured daily during the ICU hospitalization. Primary endpoint was proven
CRBSI. Therapy monitoring as according to infection control was also evaluated.
Results: Among the 46 patients, 26 were diagnosed with CRBSI. Median PCT on the day of infection suspicion (D0)
was 7.70 and 0.10 ng/ml for patients with and without proven CRBSI, respectively (p < 0.001). The area under the
curve (AUC) for PCT was 0.990 (95% CI; 0.972 – 1.000), whereas a cut-off value of 0.70 ng/ml provided sensitivity
and specificity of 92.3 and 100% respectively. In contrast, the AUC for white blood cells (WBC) was 0.539 (95% CI;
0.369 – 0.709), and for C-reactive protein (CRP), 0.603 (95% CI; 0.438 – 0.768). PCT was the best predictor of proven
infection. Moreover, an increase >0.20 ng/ml of PCT between the D0 and any of the 4 preceding days was
associated with a positive predictive value exceeding 96%. PCT concentrations from the D2 to D6 after suspected
infection tended to decrease in controlled patients, whereas remained stable in non-controlled subjects. A PCT
concentration exceeding 1.5 ng/ml during D3 was associated with lack of responsiveness to therapy (p = 0.028).
Conclusions: We suggest that PCT could be a helpful diagnostic and prognostic marker of CRBSI in critically ill
patients. Both absolute values and variations should be considered.
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Background
Use of central venous catheters (CVC) is essential in car-
ing for critically ill patients. However, despite new know-
ledge in the pathogenesis [1] and prevention [2,3],
catheter-related bloodstream infections (CRBSIs) still re-
main a leading cause of health-care-associated infections
[4], and are related with significant morbidity, mortality,
and hospital cost [5,6].
Conventional approach to managing this type of in-
fection requires a decision making regarding the re-
moval or sparing of the indwelling catheter and the
early institution of empirical antimicrobial therapy [6].
Furthermore, antibiogram-guided antibiotic treatment
and repeated blood cultures for assessing control of in-
fection, follows. However, the above practice is often
problematic, mainly because classical criteria that are
often associated with CRBSI, such as fever, chills, or
hypotension are too nonspecific to establish a diagnosis
[6]. In addition, the majority of CRBSI occurs in the ab-
sence of local symptoms [7]. Since critically ill patients
have many reasons to develop systemic inflammatory
response syndrome (SIRS), there is a tendency to as-
sume that many patients with a CVC in place might
suffer from CRBSI. Unfortunately, up to 70% of the
central venous catheters removed due to suspected in-
fection, prove to be sterile [5].
Therefore, diagnosis of CRBSI by a catheter-sparing
method with a high degree of accuracy is essential. For
this purpose, microbiological characteristics such as dif-
ferential time to positivity, simultaneous quantitative
blood cultures, or the time to positivity of blood cultures
[8,9] have been suggested to be discriminative. However,
time delay of several days and increased cost are consid-
ered major disadvantages. In addition, some of these
techniques are labour intensive.
On the other hand, the results of therapy delay,
regarding the proportion of survival, are well established
in septic shock [10], and as it was suggested, prompt in-
stitution of appropriate therapy, along with removal of
indwelling catheter is essential for successful infection
control [11].
In this respect, such infections are often overdiag-
nosed, resulting in unnecessary and wasteful removal of
the indwelling vascular catheter and antibiotic overuse,
favoring at the same time potential emerging of multi-
drug resistant organisms. Unfortunately, commonly used
biomarkers, such as WBC or CRP lack adequate specifi-
city for diagnosis of bacterial infections [12].
In this context, we have hypothesized that measure-
ment of PCT [13], which is a fast-reacting biomarker,
could be a useful method for early diagnosis and therapy
monitoring of CRBSIs in critically ill patients. A plethora
of clinical observational studies have evaluated diagnos-
tic accuracy of PCT for discriminating patients with
SIRS versus sepsis [14,15]. In addition, several trials have
shown that the use of PCT-guided algorithms towards
antibiotic stewardship programs is capable to reduce the
consumption of antibiotics in septic patients [16,17].
However, different meta-analyses have obtained con-
flicting results regarding reliability of PCT in diagnos-
ing sepsis or bacteremia [18,19]. In this respect, it has
been emphasized that PCT must always be interpreted
in the context of a careful clinical and microbiological
assessment [20].
There are only a few studies in the literature that
have assessed the accuracy of PCT for CRBSI diagnosis
[21,22]. Chen and colleagues [21] assessed PCT dis-
criminative value in terms of CRBSI diagnosis in a
group of liver transplanted patients, whereas Schuetz
et al. [22] studied a cohort of medical patients with dif-
ferent diagnoses. However, both research groups did
not mention either if they recruited patients under
mechanical ventilator support, or if studies were per-
formed in the ICU.
Thus, the aim of the present study was to evaluate
the accuracy of PCT serum levels and its kinetics, be-
fore development of a suspected infection, for diagnos-
ing CRBSI in critically ill patients during their stay in
the ICU. Moreover, we tried to compare its discrimin-
ating power with other biomarkers, such as WBC
count and CRP serum levels, during an episode of sus-
pected infection. The prognostic role of serial PCT
measurements as monitoring to infection control was
also assessed.
Methods
This observational cohort study was performed in a
nine-bed medico-surgical ICU in the teaching hospital
of Alexandroupolis, Greece, between June 2008 and May
2011. The hospital ethics committee on human research
approved the study protocol and informed consent was
obtained from the patients’ next of kin.
One hundred and 2 patients admitted to the ICU
and suspected to stay longer than 48 h with a central
vascular catheter in place, were included in the study
(Figure 1). The primary outcome was proven CRBSI.
Procalcitonin measurements were obtained daily. CRBSI
was suspected if patients met simultaneously all the
following criteria: 1) clinical manifestations of infection
(e.g., fever, chills, and/or hypotension) 2) central venous
catheter being in place for more than 48 h and 3) no other
apparent source of infection [6,23]. For suspected CRBSI,
paired blood samples (10 ml) from catheter and a per-
ipheral vein were obtained and together with a 5-cm
segment of the catheter tip removed, were submitted
for culture [6]. Subsequently, antibiotic therapy was
initiated empirically, according to our local antimicrobial
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susceptibility data and included: meropenem, gentamicin
and vancomycin.
Definitive diagnosis of CRBSI, according to published
guidelines [6] required: 1.either the isolation of the same
organism from one peripheral blood culture and the cul-
ture of the catheter tip (criterion 1), or 2. positive cul-
ture obtained from both the catheter hub and blood
from peripheral vein (criterion 2), meeting CRBSI cri-
teria for differential time to positivity (DTP) [6]. The
semiquantitative (roll-plate) method was used for the
catheters tip cultures with a colony count of 15 CFU/ml
or more suggesting significant growth.
Exclusion criteria were any active infection upon ICU
admission and infection other than CRBSI during ICU
hospitalization (56 patients, Figure 1). If a patient had
more than one episodes of suspected CRBSI during the
study period, only the first episode was included in the
study. In this respect, from the 46 remaining patients, 20
subjects were proven not to suffer a CRBSI (not proven
CRBSI) and 26 were positive for catheter-related blood
stream infection (proven CRBSI).
Acute Physiology and Chronic Health Evaluation
(APACHE) II score and Sequential Organ Failure As-
sessment (SOFA) score of severity of illness were calcu-
lated upon admission and on a daily basis, respectively.
Patients who had undergone any surgery in the 4 weeks
preceding admission were considered surgical admis-
sions. All other admissions were considered as medical.
Patients were evaluated daily for clinical suspicion of in-
fection and appropriate cultures from any potential site,
as clinically indicated, were obtained, according to the
principles of source control in the sepsis management
[11]. SIRS and sepsis were defined according to pub-
lished guidelines [24].
For management monitoring purposes patients with
proven CRBSI were categorized in two subgroups de-
pending on the infection control: a. Controlled, i.e.
patients with controlled infection (n = 16), defined as
clinical and microbiological improvement and b. Not
controlled, i.e. defined as persistent bacteremia (the
same pathogen responsible for episode 1 was cultured
72 h after catheter removal), superinfection (CRBSI due
to another pathogen during therapy period), or death
related to CRBSI (Figure 1). The empirical antibiotic
therapy was considered appropriate if the isolated pat-
hogen(s) was (were) susceptible to at least one drug
administered at the onset of sepsis, according to the cor-
responding susceptibility test.
Day 0 (D0) was reported the first day of suspected
CRBSI. The previous days were marked as (−). Duration
of treatment of CRBSI was made following the relevant
guidelines [6].
Blood samples for routine hematology and biochemis-
try panels, as well as PCT and CRP levels were measured
within the first 24 h of admission, and then daily
between 8.00 and 9.00 a.m. PCT was measured by the
automated immuno-luminometric method (Liaison
Brahms PCT, DiaSorin, Italy) with a detection limit of
0.03 ng/ml and a functional sensitivity of 0.24 ng/ml,
according the manufacturer’s instructions. During treat-
ment physicians in charge were not blinded but did not
use PCT for clinical decision making.
Statistical analysis
Statistical analysis of the data was performed using
the SPSS, version 19.0 (SPSS, Inc., Chicago, IL, USA).
The normality of quantitative variables was tested by
Kolmogorov-Smirnov test. Normally distributed variables
Figure 1 Flow chart of the study, CVC: Central venous catheter; ICU: Intensive care unit; CRBSI: Catheter - related bloodstream
infection.
Theodorou et al. BMC Infectious Diseases 2012, 12:247 Page 3 of 10
http://www.biomedcentral.com/1471-2334/12/247
were expressed as mean ± standard deviation (SD), while
non-normally distributed variables were expressed as me-
dian with interquartile range (IQR). The differences of all
variables between groups were assessed by Student’s t test
or Mann–Whitney U test, while within groups differences
of PCT values were examined by Friedman test; post hoc
analysis was performed using Bonferonni’s correction. Cat-
egorical variables were expressed as frequencies and per-
centages (%) and they were analyzed using the Chi-square
test. The area under the receiver-operating-characteristics
curve (ROC) was calculated to evaluate the diagnostic and
prognostic significance of the tested parameters. Sensitiv-
ity, specificity, positive and negative predictive values were
also calculated. The value with the shortest distance from
the curve to the point with both maximum sensitivity and
specificity, i.e., the point (0.0, 1.0), was selected as the opti-
mal cut-off point, whereas AUC differences between stud-
ied parameters were assessed with Hanley and McNeil
test. All tests were two tailed and a p < 0.05 was consid-
ered statistically significant for all analyses.
Results
Characteristics of the study population on admission
The demographic and clinical characteristics of patients
on admission and final outcome are summarized in
Table 1. No statistically significant differences were found
in terms of age, gender, origin, causes of admission,
APACHE II score, SOFA score, presence of SIRS, comor-
bidities, and ICU mortality. Furthermore, it was found
that the two groups were comparable in terms of WBC
count, CRP, and PCT values. In patients with proven
CRBSI the ICU length of stay was significantly longer in
comparison with patients with not proven CRBSI.
Microbiology results
Among the 26 patients with proven CRBSI, 22 (84.6%)
exhibited gram–negative bacteremia and 6 (23%) gram–
positive bacteremia. Microorganisms considered respon-
sible for CRBSI were: Acinetobacter baumanii (n = 12),
Klebsiella pneumoniae (n = 6), Pseudomonas aeruginosa
(n = 3), E coli (n = 1), methicillin-resistant Staphylococ-
cus aureus (n = 1), methicillin-sensitive Staphylococcus
aureus (n = 1), and coagulase-negative staphylococci
(n = 4). Two patients had more than one pathogen.
Group with patients suffering not controlled infection
included: 3 patients with persistent bacteremia, 2
patients with persistent bacteremia and superinfection,
and 5 patients who died because of CRBSI. The isolated
pathogens of patients with not controlled infection were
mainly Gram-negative organisms and included: Klebsi-
ella pneumoniae (3 cases), Pseudomonas aeruginosa
(3 cases), Acinetobacter baumanii (3 cases); only one pa-
tient exhibited Gram-positive bacteremia (Coagulase-
negative staphylococcus). One-half of patients with not
controlled infection due to Gram-negative bacteria were
given inappropriate empirical antibiotics within the first
3 days of sepsis management, whereas empirical anti-
biotic therapy was appropriate in all patients with con-
trolled CRBSI.
Day of infection (D0)
Clinical characteristics of the 2 groups of patients on the
day of infection suspicion (D0) are presented in Table 2.
Time of CVC being in place and time elapsed from ICU
admission until D0 did not differ between the 2 groups
of patients. Moreover, patients did not differ in terms
Table 1 Patient’s demographics and clinical
characteristics on admission and final outcome
Not proven CRBSI Proven CRBSI P
n= 20 n=26
Age [years; mean (SD)] 44.45 (19.75) 51.73 (19.95) 0.224a
Male gender [no (%)] 10 (50.0) 18 (69.2) 0.185b
Origin [no (%)]
Medical 9 (45.0) 12 (46.2) 0.938b
Surgical 11 (55.0) 14 (53.8)
Reason of admission
[no (%)]
Neurological 13 (65.0) 12 (46.2) 0.203b
Respiratory 1 (5.0) 2 (7.7) 0.714b
Surgical 1 (5.0) 4 (15.4) 0.262b
Trauma 4 (20.0) 6 (23.0) 0.802b
Other 1 (5.0) 2 (7.7) 0.714b
APACHE II score
[mean (SD)]
22.45 (4.32) 20.65 (4.69) 0.190a
SOFA score
[mean (SD)]
7.15 (1.57) 6.81 (2.53) 0.598a
Presence of SIRS
[no (%)]
6 (30.0) 9 (34.6) 0.741b
Co-morbidities
Malignancy [no (%)] 1 (5.0) 2 (7.7) 0.714b
Diabetes mellitus [no (%)] 2 (10.0) 3 (11.5) 0.868 b
Steroids [no (%)] 2 (10.0) 3 (11.5) 0.868b
Heart failure [no (%)] 1 (5.0) 2 (7.7) 0.714b
WBC count [10 3/μl;
mean (SD)]
14.47 (4.2) 12.80 (4.1) 0.185a
CRP [mg/dl; median
(IQR)]
0.86 (0.50-2.65) 2.68 (0.62-10.88) 0.069c
PCT [ng/mL; median
(IQR)]
0.10 (0.10-0.20) 0.10 (0.10-0.43) 0.168c
ICU length of stay
[days; mean (SD)]
19.85 (6.99) 29.15 (11.34) 0.001a
ICU mortality [no (%)] 1 (5.0) 5 (19.2) 0.155b
a Student’s t test.
b Chi-square test.
c Mann–Whitney test.
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of presence of SIRS, development of shock, and adminis-
tration of systemic antibiotics. Among studied biomarkers,
only PCT serum levels were found significantly increased
in patients with proven CRBSI compared with patients
with not proven CRBSI [7.70 (2.50-11.43) vs. 0.10 (0.10-
0.27), (p < 0.001)]. A tendency towards higher severity of
illness was found in patients with proven infection
(p= 0.087). Among patients with proven CRBSI 6 fulfilled
the diagnostic criterion 1, 10 the criterion 2, and the
remaining 10 patients both the two criteria (Table 2).
Days D-4 to D0
As shown in Table 2, PCT serum levels were compared
between the two groups of patients in the 4 days preced-
ing D0. Although, no significant differences were found
during D-4 (p = 0.289), PCT was significantly higher
between patients with proven CRBSI during D-3
(p = 0.017), D-2 (p < 0.001), and D-1 (p < 0.001), in rela-
tion with patients with not proven CRBSI. In addition,
longitudinal changes of PCT concentration between D0
and the four preceding days were also significantly higher
in patients with proven CRBSI than in those with not
proven CRBSI (ΔPCTD-4, D0: p < 0.001; ΔPCTD-3,
D0: p < 0.001; ΔPCTD-2, D0: p < 0.001; ΔPCTD-1, D0:
p < 0.001).
PCT time course between D0 and the 4 preceding
days for the two groups of patients are shown in Figure 2.
Friedman test revealed that variation over time of PCT
levels was statistically significant within patients with
proven infection (p < 0.001), but not within patients with
not proven CRBSI (p = 0.415). In particular, for the
group with proven CRBSI, post hoc analysis showed that
the 25% elevation of marginal significance (p = 0.078) of
PCT from D-4 to D-3, was followed by a stepwise statis-
tically significant increase from D-3 to D0 (100% from
D-3 to D-2, p = 0.006; 50% from D-2 to D-1, p < 0.001;
927% from D-1 to D0, p < 0.001).
Diagnostic significance - ROC analysis
Figure 3 and Table 3 show the diagnostic accuracy of all
studied biomarkers for proven CRBSI on D0, estimated
with the area under the curve (AUC). The AUC for PCT
was 0.990 (95% CI, 0.972 – 1.000), for WBC 0.539 (95% CI,
0.369 – 0.709), and for CRP 0.603 (95% CI, 0.438 – 0.768).
Furthermore, it was found that the AUC for PCT was
significantly higher compared to the AUCs for WBC
(p<0.001) and CRP (p< 0.001) serum levels. The optimal
cut-off points for these diagnostic markers were also deter-
mined by the ROC curve (Table 3). In particular, an optimal
cut-off point of 0.70 ng/ml for PCT on D0 was found to
discriminate patients with and without CRBSI, with a sensi-
tivity of 92.3% and a specificity of 100%. A 100% Sensitivity
was obtained for a cut-off of 0.40 ng/ml (with specificity of
85%). The cut-offs for WBC and CRP serum levels were
15.64 103/μl and 16.90 mg/dl respectively and yielded mod-
erate sensitivities (WBC: 57.7%; CRP: 50%) and specificities
(WBC: 60%; CRP: 70%). PCT variations were also found to
be predictive of proven CRBSI. Thus, an increase >0.20 ng/
ml of PCT between the D0 and any of the 4 preceding days
was associated with sensitivities 96 to 100%, and specifici-
ties (all) 95%. Interestingly, 4 patients without proven
CRBSI who underwent various minimal surgical procedures
(2 cases with transcutaneous tracheotomy and 2 cases with
intracranial pressure placement) had a rise in their
PCT (≤ 0.20 ng/ml) between D0 and the 4 preceding days.
Table 2 Patient’s clinical characteristics on the day of
infection (D0), PCT kinetics the previous 4 days until D0
and diagnostic criteria for CRBSI
Not proven CRBSI Proven CRBSI P





10.70 (2.62) 11.77 (3.31) 0.242a
Catheter in place
[days; mean (SD)]
8.25 (1.41) 8.73 (2.05) 0.375a
Presence of SIRS
[no (%)]
20 (100) 26 (100) 1.0 b
WBC count
10 3/μl; mean (SD)]
14.68 (3.8) 15.37 (6.03) 0.658a
CRP [mg/dl;
median (IQR)]
12.75 (7.93-18.33) 15.78 (10.59-21.48) 0.236c
SOFA score
[mean (SD)]
5.85 (2.41) 7.19 (2.70) 0.087a
Shock [no (%)] 9 (45.0) 14 (53.8) 0.552b
PCT [ng/ml;
median (IQR)]
D-4 (20/26) d 0.15 (0.10-0.20) 0.20 (0.10-0.50) 0.289c
D-3 (20/26) d 0.10 (0.10-0.28) 0.25 (0.10-0.63) 0.017c
D-2 (20/26) d 0.10 (0.10-0.20) 0.50 (0.20-1.40) <0.001c
D-1 (20/26) d 0.10 (0.10-0.30) 0.75 (0.40-2.50) <0.001c
D0 (20/26) d 0.10 (0.10-0.27) 7.70 (2.50-11.43) <0.001c
ΔPCTD-4, D0 0.00 (−0.90-0.40) 7.05 (2.40-10.43) <0.001
c
ΔPCTD-3, D0 0.00 (−0.90-0.40) 6.45 (2.40-10.30) <0.001
c
ΔPCTD-2, D0 0.00 (−0.60-0.40) 5.55 (2.23-9.93) <0.001c










(1 + 2) [no (%)]
_ 10 (38.5)
a Student’s t test; b Chi-square test; c Mann–Whitney test; d No of patients
available for analysis (Not proven/proven).
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Prognostic value of PCT
Patients with and without controlled CRBSI were com-
pared in terms of PCT concentrations during the 6 fol-
lowing days after D0 (Figure 4). A highly significant
reduction of PCT concentration on D(1) was observed
in both groups (p = 0.002 in controlled, p = 0.005 in not
controlled). Subsequently, PCT serum levels tended to
further decrease significantly in patients with controlled
CRBSI, whereas in not controlled patients was proven to
remain stable. D3 was the first day during therapy,
where a statistically significant difference was found
between the two subgroups of patients (Table 4).
Specifically, on D3 a concentration of PCT more than
1.5 ng/ml was associated with non-response to therapy
with a sensitivity 70% and specificity 68.7% (p = 0.028).
PCT variations were also found to be predictive of non-
response to therapy (Table 4). Thus, a decrease of PCT
concentration between D1 and D2 (ΔPCT D1- D2) of
more than 1.00 ng/ml, and between D2 and D3 (ΔPCT
D2-D3) exceeding 0.30 ng/ml were associated with good
response to therapy.
Discussion
The principal findings of this study performed in
selected critically ill patients with suspected CRBSI are:
(1) the confirmation of good diagnostic accuracy of
PCT; (2) the modest discriminative value of other indi-
cators of inflammation, such as WBC, and CRP; and
(3) the good prognostic performance of PCT and PCT
kinetics as a monitoring tool to infection control during
antimicrobial therapy.
Although there is accumulating evidence that PCT is
not a “magic biomarker” [19], many studies have shown
its ability to early detect bacterial infections in critically
ill patients [18]. However, this is the first prospective ob-
servational study assessing accuracy of PCT for the diag-
nosis of CRBSI in the ICU.
According to our results, the level of PCT obtained
during the day of suspected CRBSI is a better diagnostic
marker compared with WBC and CRP. Additionally, on
the day of clinical suspicion of infection a cut-off point
of 0.7 ng/ml for PCT was proven to discriminate
patients with and without CRBSI.
Similar results were found in other selected popula-
tions [21,22], where a cut-off of 0.1 ng/ml PCT was
found to have 100% sensitivity in excluding contamin-

















Figure 2 PCT kinetics of patients with and without proven CRBSI from Day-4 (D-4) to Day 0 (D0). Results are expressed as median values
with IQR (25-75%).
Figure 3 ROC curves of PCT, WBC, and CRP on D0 for
differentiating between patients with and without proven
CRBSI in the ICU.
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Although the most commonly reported causative patho-
gens for CRBSI remain coagulase-negative staphylococci
[6], in our cohort gram-negative bacteria were predomin-
antly recovered from patients with proven CRBSI. This
may be due to the fact that our patients were critically ill
with prolonged ICU length of stay (Table 2). Since this
special group of patients is usually colonized with gram-
negative multi-resistant bacteria, the vast majority of
CRBSI have been found to be of gram-negative origin
[15,25]. It has been shown that in critically ill patients, GN
bacteremia could be associated with higher PCT values
than those found in GP bacteremia [26]. This could ac-
count for the fact that in our study, PCT elevations were
higher than those from the study of Schuetz et al. [22].
It is well established that non-specific elevations of
PCT serum levels in the absence of a bacterial infection
can be seen in situations of severe stress, such as trauma
or postoperatively [12]. Because more than half of our
patients were of surgical origin, we considered that the
assessment of PCT kinetics could overcome this draw-
back. In this respect, we have shown that an increase of
PCT more than 0.20 ng/ml, between the day of clinical
suspicion of CRBSI and any of the 4 preceding days, is
associated with significant diagnostic accuracy for CRBSI
(sensitivities > 96%, and specificities 95%).
Our findings are similar with those reported in two re-
cent studies that tried to assess PCT’s diagnostic value
for early detection of different infections in the ICU
[14,15].
However, the authors did not evaluate specifically
CRBSI, and a proportion of their patients had been suf-
fering previous septic episodes.
In addition, the diagnostic accuracy of PCT in our
study was better compared with findings from the previ-
ous studies [14,15]. We believe that this may be due to
several factors. First of all, our patients were not suffer-
ing from any previous infection during enrollment in the
study, a criterion that may enhance the diagnostic per-
formance of PCT [27]. Moreover, only a small propor-
tion of our patients’ population (23%) was receiving
antibiotics at the time of suspected infection. This prac-
tice may affect the interpretation of PCT as a diagnostic
method [27,28]. Furthermore, we have shown that
patients with proven CRBSI had significantly higher
PCT levels not only during D0, but also during the three
preceding days. This increase of PCT prior to the
Table 3 Diagnostic significance of PCT, PCT kinetics, WBC, and CRP for CRBSI during ICU stay
AUC (95% CI) Cut-off Sensitivity (%) Specificity (%) PPV (%) NPV (%) LR(+) LR(−) Accuracy (%)
PCT D0 [ng/ml] 0.990 (0.972 – 1.000) >0.70 92.3 (73.4 – 98.7) 100 (80.0 – 100) 100.0 90.9 n.a. 0.08 95.7
ΔPCTD-1, D0 [ng/ml] 0.982 (0.941 – 1.000) >0.20 100 (84.0 – 100) 95.0 (73.1 – 99.7) 96.3 100.0 20.0 0.0 97.8
ΔPCTD-2, D0 [ng/ml] 0.992 (0.975 – 1.000) >0.20 100 (84.0 – 100) 95.0 (73.1 – 99.7) 96.3 100.0 20.0 0.0 97.8
ΔPCTD-3, D0 [ng/ml] 0.980 (0.939 – 1.000) >0.20 96.2 (78.4 – 99.8) 95.0 (73.1 – 99.8) 96.2 95.0 19.2 0.04 95.6
ΔPCTD-4, D0 [ng/ml] 0.982 (0.946 – 1.000) >0.20 96.2 (78.4 – 99.8) 95.0 (73.1 – 99.8) 96.2 95.0 19.2 0.04 95.6
WBC D0 [10 3/μl] 0.539 (0.369 – 0.709) >15.64 57.7 (37.2 – 76.0) 60.0 (36.4 – 80.0) 65.2 52.2 1.44 0.71 58.7
CRP D0 [mg/dl] 0.603 (0.438 – 0.768) >16.90 50.0 (30.4 – 69.6) 70.0 (45.7 – 87.2) 68.4 51.9 1.67 0.71 58.7

















Figure 4 PCT kinetics of controlled and not controlled patients with CRBSI from Day 0 (D0) to Day 6 (D+ 6). Results are expressed as
median values with IQR (25-75%).
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clinical manifestation of infection is an important find-
ing of our study and parallels results from Schuetz et al.
[22]. Interestingly, as they concluded “this early increase
may reflect the colonization of the catheter with subclin-
ical infection eventually leading to CRBSI” [22].
Charles et al. found a significant decrease of PCT be-
tween the second and third day after the onset of sepsis
in critically ill patients treated with appropriate anti-
biotic therapy [29]. In the present study, it has been
demonstrated that PCT kinetics during the first 3 days
of therapy could discriminate responders from non-
responders, in terms of antimicrobial treatment. More-
over, a PCT concentration exceeding 1.5 ng/ml on the
third day of treatment seems to be prognostic for lack of
response to therapy.
Some limitations of our study should be noted. First,
population sample was relatively small, so these results
need to be confirmed in larger studies. Second, the
included patients were relatively young, with a low rate
of underlying disease. In addition they were mainly of
surgical origin with neurological and trauma admission
diagnosis. Consequently, the findings of our study can-
not be extrapolated to other groups of critically ill
patients. In addition, we had excluded all patients with
any other infection during ICU hospitalization and used
a control group without infection. In this respect, our
study population included patients that were clearly dif-
ferent from those the ICU physician use to deal with in
the ICU setting, where patients might have fever from
different infectious and non- infectious causes. Although
this limitation represents a weakness of our study, on
the same time we believe is one of its strength, since
withdrawn of potential confounders may increase useful-
ness of different biomarkers, as diagnostic and monitor-
ing tools, in daily practice. Therefore, because of the
lack of a comparative group having fever due to other
etiologies, the true accuracy of PCT in ICU patients with
CRBSI need to be confirmed in larger studies including
more complex patients with fever and systemic inflam-
mation. In addition, since the diagnostic accuracy of
PCT and its optimal cut-offs are dependent on the use
of a sensitive assay [12], the fact that the Kryptor test
was not available for serum PCT measurement, is an-
other limitation of our study. Finally, the high PCT
levels observed in patients with CRBSI could be the re-
sult of another concurrent infection. However, this
seems unlikely since every effort was made to early iden-
tify and exclude patients with other causes of infection,
even after proven CRBSI diagnosis.
In conclusion, we suggest that PCT could be an appro-
priate method for diagnosis of CRBSI. In addition, its
adoption in every day clinical practice could prevent un-
necessary withdrawing of thousands of central venous
catheters, limiting at the same time inappropriate use of
empirical antimicrobial therapy. Moreover, PCT seems
to have some prognostic value regarding therapeutic
monitoring. Thus, its course, even in the first 3 days of
therapy, could predict non-responders with CRBSI, and
might help clinicians to make a proper and early deci-
sion concerning therapeutic alternatives (i.e., resistance
to administered empirical antibiotic treatment needing
shift to another therapeutic combination or possibly
complicated CRBSI, such as development of suppurative
thrombophlebitis, urging a more extended diagnostic
work-up).
Conclusions
We suggest that PCT serum levels and PCT kinetics
could serve as early and accurate markers for the
diagnosis and prognosis of CRBSIs in the ICU setting,
associated with clinical findings. However, larger ob-
servational studies, and clinical trials would be the
best way to demonstrate the impact of PCT in ICU
patients with suspected CRBSI. Moreover, our results
need external validation in a more heterogeneous group
Table 4 Patient’s clinical characteristics on the day of
infection (D0) and PCT kinetics the next 6 days after
diagnosis of CRBSI
Controlled Not controlled P




15.69 (6.9) 14.87 (4.5) 0.745a
CRP [mg/dl;
median (IQR)]
15.78 (10.06-21.05) 15.65 (10.55-25.75) 0.732c
SOFA score
[mean (SD)]
6.56 (2.19) 8.20 (3.22) 0.135a
Shock [no (%)] 7 (43.8) 7 (70.0) 0.191b
PCT [ng/mL;
median (IQR)]
D0 (16/10) d 7.55 (2.50-13.67) 8.30 (2.07-11.35) 0.771c
D+ 1 (16/10) d 2.50 (1.53-10.52) 3.00 (1.30-5.55) 0.635c
D+ 2 (16/10) d 1.75 (0.65-5.22) 2.70 (1.22-4.27) 0.635c
D+ 3 (16/10) d 0.55 (0.50-3.10) 2.60 (0.75-5.12) 0.047c
D+ 4 (16/10) d 0.50 (0.23-2.15) 2.40 (0.67-6.00) 0.042c
D+ 5 (16/10) d 0.20 (0.13-0.72) 2.40 (0.35-8.17) 0.009c
D+ 6 (16/9) d 0.20 (0.12-0.50) 2.10 (0.20-12.25) 0.012c
ΔPCTD0, D+1 −2.65 (−8.90 to −0.75) −4.60 (−5.63 to −0.78) 0.895
c
ΔPCTD+1, D+2 −1.65 (−5.45 to −0.38) −0.30 (−1.30 to −0.08) 0.037
c
ΔPCTD+2, D+3 −1.00 (−2.68 to −0.15) −0.05 (−0.45 to 0.25) 0.017
c
ΔPCTD+3, D+4 −0.15 (−1.65 to −0.03) −0.15 (−0.28 to 0.73) 0.253c
ΔPCTD+4, D+5 −0.25 (−0.68 to −0.12) −0.10 (−0.33 to 0.75) 0.085c
ΔPCTD+5, D+6 0.00 (−0.10 to 0.08) 0.00 (−0.45 to 0.20) 0.872c
a Student’s t test; b Chi-square test; c Mann–Whitney test; d No of patients
available for analysis (Controlled/Not controlled).
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of patients with other possible etiologies of infection and
systemic inflammation.
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